Previous therapy with at least radiotherapy and temozolomide
No previous radiotherapy, chemotherapy or other brain tumor directed therapy other than corticosteroid therapy and surgery
Patients must have no previous radiotherapy or chemotherapy other than corticosteroids
Previous first line treatment with at least radiotherapy.
 day wash-out period from any previous chemotherapy, targeted therapy or radiotherapy,  day washout period from previous immunotherapy
Dispositioned to single modality photon radiotherapy (i.e. no chemotherapy or previous therapeutic intent surgery).
Previous chest radiotherapy
Previous first line therapy with at least radiotherapy
Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy
Previous extensive radiotherapy to the lung or liver during the last  months prior to lymphodepletion regimen.
Previous radiotherapy within  months before study entry
No chemotherapy or radiotherapy within the past  days and patients must have recovered any acute toxicity associated with their most recent previous treatment
Patients who received previous radiotherapy to the brain
Previous radiotherapy to the lung or mediastinum
Previous radiotherapy of the tumor bed (for ACC).
Previous radiotherapy to the brain.
Participants who have received any chemotherapy or radiotherapy for previous malignancy are not eligible
Previous first line treatment with at least standard dose of radiotherapy (total dose >=  Gy) and temozolomide
Subjects must have recovered from all toxicity associated with previous chemotherapy,\n             targeted therapy, or radiotherapy
Previous radiotherapy to the lesion(s) of interest
Previous radiotherapy (XRT) or chemotherapy
Previous stereotactic or highly conformal radiotherapy within  weeks before the start of dosing for this study. Note the stereotactic radiotherapy field must not have included the brain index lesion(s)
Previous first line therapy with at least radiotherapy and temozolomide.
Previous lung or mediastinal radiotherapy
Previous first line treatment with at least standard dose of radiotherapy (total dose >=  gray [Gy]) and temozolomide
Any previous systemic chemotherapy for cancer or radiotherapy for cancer
Previous radiotherapy within  weeks of starting study therapy.
Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy
Previous first line therapy with at least radiotherapy and temozolomide
Previous whole brain radiotherapy
Previous treatment with radiotherapy and temozolomide (Cohorts , b and  only)
Previous chemotherapy, radiotherapy of other treatment for PC
Glioblastoma disease-specific concerns: Patients must not have received previous or concurrent radiotherapy to the brain
No previous radiotherapy or chemotherapy other than corticosteroid therapy
Persistence of toxicity from previous chemo and/or radiotherapy > grade 
Previous radiotherapy to the pelvis
Previous whole brain radiotherapy (WBRT)
Subjects who are currently receiving or have had previous hormonal, chemotherapy, or radiotherapy for prostate cancer
Cancer diagnosis or received treatment (chemotherapy or radiotherapy) for malignancy within the previous  months
Previous brain radiotherapy
No previous radiotherapy or systemic treatment for SCCHN